Kurapov A P, Starodubtsev A K, Rubtsova T M, Ignat'ev V G, Kemenova V A
Eksp Klin Farmakol. 1995 Jan-Feb;58(1):53-4.
Ortopak tablets, 100 mg, were investigated. The pharmacokinetics of Ortopak was studied in 10 rheumatoid arthritis patients after a single oral dose of 100 mg. Ortophenum and voltaren-retard (Ciba-Geigy) were used for comparison. Diclophenac-sodium was measured in the patient's plasma by using high performance liquid chromatography. Ortopak was shown to be eliminated from the patient's body much slower than Ortophenum. The bioequivalence of Ortopak versus Ortophenum was 62.7%. The pharmacokinetic properties of Ortopak were similar to those of Voltaren-retard, which were close to those of diclophenac-sodium in the blood plasma within the therapeutic range.
对100毫克的奥拓帕克片剂进行了研究。在10名类风湿性关节炎患者单次口服100毫克后，对奥拓帕克的药代动力学进行了研究。使用奥拓芬和扶他林缓释片（汽巴 - 嘉基公司）作为对照。采用高效液相色谱法测定患者血浆中的双氯芬酸钠。结果显示，奥拓帕克从患者体内消除的速度比奥拓芬慢得多。奥拓帕克与奥拓芬的生物等效性为62.7%。奥拓帕克的药代动力学特性与扶他林缓释片相似，在治疗范围内，其在血浆中的特性与双氯芬酸钠相近。
